Regulus Therapeutics Inc.
RGLSDelisted Jun 25, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001505512
Regulus Therapeutics Inc. was delisted on Jun 25, 2025; its insiders filed their last Form 4 on Jun 27, 2025; 75 institutions reported holding it in 13F filings for Q1 2025, worth $107.0M in total; no superinvestor held it.
Q4 2021 vs. Q3 2021
How the institutions holding Regulus Therapeutics Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Of which not filed for Q4 2021 | Q4 2021 | Change |
|---|---|---|---|---|
| Holders | 42 | 1 | 38 | −3 |
| Shares | 23.0M | 16 | 30.2M | +7.21M (+31.4%) |
| Value | $15.9M | $0 | $9.54M | −$6.32M (−39.9%) |
1 institution that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (7)
Institutions that held Regulus Therapeutics Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| DAFNA Capital Management LLC | 5,555,555 | $1.75M | 0.44% |
| Empery Asset Management, LP | 5,074,251 | $1.60M | 3.34% |
| Two Sigma Investments, LP | 55,306 | $17.0K | 0.00% |
| Jane Street Group, LLC | 24,426 | $8.00K | 0.00% |
| Renaissance Technologies LLC | 22,300 | $7.00K | 0.00% |
| Endurance Wealth Management, Inc. | 6,750 | $2.00K | 0.00% |
| Tower Research Capital LLC (TRC) | 6,841 | $2.00K | 0.00% |
Sold out (10)
Institutions that held Regulus Therapeutics Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Endurant Capital Management LP | 3,547,208 | $2.45M |
| Bank of America Corp | 393,307 | $271.0K |
| Acadian Asset Management LLC | 246,191 | $170.0K |
| Susquehanna International Group, LLP | 164,155 | $113.0K |
| Gsa Capital Partners LLP | 64,708 | $45.0K |
| Citadel Advisors LLC | 35,357 | $24.0K |
| Cambridge Investment Research Advisors, Inc. | 14,000 | $10.0K |
| Manufacturers Life Insurance Company, The | 10,610 | $7.00K |
| AdvisorNet Financial, Inc | 7,500 | $5.00K |
| Barclays PLC | 50 | $0 |
Not filed for Q4 2021 yet (1)
Institutions that held Regulus Therapeutics Inc. at the end of Q3 2021 and haven't filed a 13F for Q4 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Sonora Investment Management, LLC | 16 | $0 |